Revenue and Profitability - The company's revenue for Q1 2024 was ¥184,532,679.41, representing a 17.42% increase compared to ¥157,152,422.97 in the same period last year[5]. - The net profit attributable to shareholders decreased by 10.22% to ¥22,737,202.98 from ¥25,325,308.14 year-on-year[5]. - Basic earnings per share decreased by 9.52% to ¥0.38 from ¥0.42 in the same period last year[5]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 19.57 million, reflecting a year-on-year growth of 7.74%[14]. - The total comprehensive income attributable to the parent company for Q1 2024 was ¥22,737,202.98, a decrease from ¥25,325,308.14 in Q1 2023, representing a decline of approximately 10.5%[21]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at -¥8,550,816.03, a decline of 148.42% compared to ¥17,660,682.50 in the previous year[5]. - Cash inflows from operating activities totaled ¥170,027,073.63, down from ¥181,477,062.22 in the previous year, reflecting a decrease of approximately 6.5%[24]. - The net cash flow from investment activities was ¥81,122,056.14, a turnaround from a negative cash flow of -¥1,118,431.51 in Q1 2023[24]. - The total cash and cash equivalents at the end of Q1 2024 were ¥564,307,218.74, down from ¥692,603,148.66 at the end of Q1 2023, a decrease of approximately 18.5%[24]. - The company's cash and cash equivalents increased to RMB 564.31 million from RMB 493.33 million at the beginning of the period[16]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,371,068,862.97, a slight increase of 0.31% from ¥1,366,819,029.33 at the end of the previous year[5]. - Total liabilities decreased to ¥264,852,099.81 from ¥286,223,762.86 year-over-year, a reduction of 7.4%[18]. - The company reported a decrease in trading financial assets from RMB 421.14 million to RMB 340.78 million[16]. - Accounts receivable decreased from RMB 124.21 million to RMB 113.30 million[16]. - The company reported a decrease in accounts payable to ¥1,859,511.92 from ¥2,593,586.53, a decline of 28.3%[18]. Expenses and Investments - Sales expenses rose by 36.14% to ¥2,088,982.69 due to increased personnel costs and marketing activities[10]. - Research and development expenses increased to ¥8,664,189.05, compared to ¥6,857,112.53 in Q1 2023, reflecting a growth of 26.4%[20]. - Investment income surged by 204.32% to ¥2,632,521.24, primarily from gains on structured deposits[10]. - The company reported a significant increase in fair value gains of 1,291.54% to ¥784,370.99, attributed to the appreciation of structured deposits[10]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,596[12]. - The chairman and actual controller, Lai Chunbao, announced a plan to increase his shareholding by investing between RMB 5 million and RMB 8 million, successfully acquiring 160,000 shares for RMB 6.54 million[15]. Company Operations - As of the end of the reporting period, the company had a total of 4,407 employees, with over 4,200 being professional staff, serving more than 930 clinical trial institutions[14]. - The company continues to expand its service coverage, reaching over 1,300 clinical trial institutions across more than 190 cities in China[14]. - The company has undertaken over 3,100 international and domestic SMO projects, with 1,885 projects currently in execution[14]. Future Outlook - The company has not yet audited the Q1 2024 report[25]. - The company is set to implement new accounting standards starting in 2024, which may affect future financial reporting[25].
普蕊斯(301257) - 2024 Q1 - 季度财报